Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid neoplasm which shows a high rate of central nervous system (CNS) recurrence and overall survival (OS) of <1 year. Despite this, screening for CNS involvement is not routinely performed at diagnosis and intrathecal (IT) prophylaxis is not regularly administered in BPDCN. Here, we prospectively evaluated 13 consecut...

Primary testicular lymphoma (PTL) is a rare and aggressive form of extranodal lymphoma. Approximately 80-98% of PTLs are diffuse large B-cell lymphoma (PT-DLBCL). The prognosis of DLBCL patients has improved with the addition of rituximab to systemic chemotherapy, but outcomes of PT-DLBCL remain poor. This may be explained by the high rate of relapse in the central nervous system (CNS) and cont...

Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use of cranial irradiation as central nervous system (CNS)-directed therapy, even ...

We employed three courses of intermediate dose Methotrexate (IDM) added onto a standard induction and maintenance program with the concept of both central nervous system (CNS) prophylaxis and simultaneous systemic intensification. Cranial radiation (RT) was not employed as CNS prophylaxis. Fifty of 52 patients (to age 18) achieved complete remission. Time on study now ranges from 22-68 months w...

Hypopituitarism in leukemia is very rare. In addition, central nervous system (cns) relapse and leukemic retinopathy in childhood acute lymphoblastic leukemia (all) have declined with the use of modern systemic chemotherapy that includes cns prophylaxis. Here, we report the case of a 4-year-old girl who received chemotherapy and intrathecal therapy without cns radiation after a diagnosis of B-p...

Introduction: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a rare event, occurring in about 5% patients (pts) and correlating with very dismal prognosis. Much debate has surrounded the use strategies to avert CNS disease recurrence. Nowadays, prophylaxis mostly based on high-dose intravenous (iv) methotrexate (HD-MTX), but its effectiveness controversial. Our...

Central nervous system (CNS) relapse affects 5% of diffuse large B-cell lymphoma (DLBCL) patients and portends a poor prognosis. Prophylactic intravenous high-dose methotrexate (HD-MTX) is frequently employed to reduce this risk, but there limited evidence supporting practice. We conducted multicenter retrospective study determine the CNS risk with HD-MTX in DLBCL aged 18–70 years treated Alber...

Introduction: We analyzed the incidence, risk factors of central nervous system (CNS) relapse and outcome CNS involvement in patients with peripheral T-cell lymphomas (PTCL) prospectively observed Czech Lymphoma Study Group Registry (NCT03199066). Methods: Out 1040 we identified 29 (2.79%) involvement: 13 (1.25%) had disease at initial diagnosis 16 (1.54%) relapse. Median age was 61 years 54.5 ...

Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer and may exhibit central nervous system (CNS) involvement. Advances in chemotherapy and effective CNS prophylaxis have significantly decreased the incidence of CNS relapse of ALL to 5-10%. Here, we report the case of a patient with isolated CNS relapse of standard risk group pre-B-cell type ALL in an 11-year-old girl,...

To the Editor: There remains a lack of consensus regarding efficacy high-dose methotrexate (HD-MTX) prophylaxis to reduce risk central nervous system (CNS) relapse in newly diagnosed patients with systemic diffuse large B-cell lymphoma (DLBCL). The clinical controversy reflects high-quality evidence supporting optimal strategies, coupled poor outcomes who experience CNS relapse. Interest this a...